论文部分内容阅读
20世纪80年代初期开始用淋巴因子激活的杀伤细胞(LAK)和肿瘤浸润淋巴细胞(TIL)对肿瘤进行细胞免疫治疗。随着对TIL所识别的肿瘤抗原的认识,这些抗原被制成各种疫苗,这些疫苗可以单用或与树突状细胞(DC)联用来抗击肿瘤。本文综述了过去18年来细胞免疫治疗的发展和对肿瘤的疗效。
Tumor immunotherapy was initiated with lymphokine-activated killer cells (LAKs) and tumor infiltrating lymphocytes (TILs) in the early 1980s. With the recognition of TIL-recognized tumor antigens, these antigens are made into various vaccines that can be used alone or in combination with dendritic cells (DCs) to combat tumors. This article reviews the development of cellular immunotherapy over the past 18 years and its efficacy in treating cancer.